Loading your page…
Leukemia research reports
By Tarafder S and Haque SA.
Mixed-phenotype acute leukemia (MPAL) is a rare but difficult to treat hematologic malignancy.
flow cytometry immunophenotyping method was used in EDTA bone marrow and/or peripheral blood taken from all consecutive morphologically diagnosed acute leukemia (AL) patients from November 2015 to December 2019.
Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.
Among 616 consecutive AL cases diagnosed and evaluated during this period, 22(3.57%) patients with MPAL were identified fulfilling WHO 2008 criteria for immunophenotypic characteristics of AL. Fifteen (68.2%) cases were diagnosed as B/myeloid, 5(22.72%) as T/myeloid and 2 (9.1%) as B/T MPAL. Morphologically diagnosed 15 (68.2%) AML cases were immunophenotypically B/Myeloid MPAL (12/15) and 3/15 cases were T/Myeloid MPAL. Morphologically 7 (31.8%) were ALL of which immunophenotypically 3/7 cases were B/Myeloid MPAL, 2/7 cases were T/Myeloid MPAL and 2/7 were B/T MPAL.
Multiparametric flow cytometry using comprehensive panel of monoclonal antibodies is a valuable tool to diagnose MPAL known to have a poor outcome.
Published in Leukemia research reports. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
